middl
east
respiratori
syndrom
coronaviru
merscov
caus
fatal
infect
hospitalacquir
transmiss
affect
region
sinc
emerg
although
viru
pandem
among
human
pose
great
threat
public
health
due
zoonot
origin
thu
prevent
therapeut
countermeasur
urgent
need
studi
discov
panel
neutral
monoclon
antibodi
mab
merscov
map
wide
rang
region
spike
protein
viru
addit
mab
neutral
epitop
locat
receptorbind
domain
one
mab
bind
ntermin
domain
ntd
merscov
subunit
show
effici
neutral
activ
wildtyp
merscov
strain
half
maxim
inhibitori
concentr
conclud
novel
neutral
epitop
merscov
also
resid
ntd
protein
indic
ntd
might
import
viral
infect
process
find
signific
implic
vaccin
design
develop
prophylact
therapeut
monoclon
immunotherapi
merscov
infect
middl
east
respiratori
syndrom
coronaviru
merscov
novel
lethal
human
pathogen
led
laboratoryconfirm
case
infect
approxim
fatal
rate
sinc
identif
saudi
arabia
symptom
caus
merscov
similar
symptom
sever
acut
respiratori
syndrom
coronaviru
sarscov
manifest
acut
sever
lower
respiratori
ill
extrapulmonari
involv
includ
vomit
diarrhea
renal
failur
infect
confirm
countri
case
occur
middl
east
follow
recent
outbreak
republ
korea
serolog
virolog
survey
indic
dromedari
camel
like
major
reservoir
merscov
although
humantohuman
transmiss
case
includ
contact
health
care
worker
famili
member
report
remain
possibl
viru
could
acquir
adapt
mutat
repeat
interspeci
transmiss
event
due
potenti
threat
merscov
list
categori
c
prioriti
pathogen
nation
institut
allergi
infecti
diseas
howev
neither
licens
vaccin
antivir
drug
merscov
approv
clinic
use
effici
countermeasur
viru
urgent
need
merscov
envelop
positivesens
singlestrand
rna
viru
belong
lineag
c
genu
merscov
genom
kb
encod
structur
protein
spikeenvelopemembranenucleocapsid
poli
highli
glycosyl
spike
protein
mediat
viral
infect
primari
determin
cell
tropism
pathogenesi
assembl
trimer
viral
particl
surfac
contain
two
function
subunit
subunit
residu
mainli
respons
mediat
viral
particl
attach
cell
surfac
depend
dipeptidyl
peptidas
receptor
subunit
residu
facilit
subsequ
fusion
viru
host
cell
membran
figur
deliv
viral
nucleic
acid
host
cell
subunit
bind
cellular
receptor
trigger
conform
chang
subunit
insert
fusion
peptid
target
cell
membran
form
sixhelix
bundl
fusion
core
prepar
viral
cell
membran
fusion
receptor
bind
domain
rbd
subunit
serv
determin
region
product
merscov
neutral
antibodi
target
develop
number
promis
merscov
vaccin
candid
merscov
rbd
map
residu
region
span
residu
locat
subunit
ctermin
domain
specif
interact
merscov
rbd
receptor
also
known
also
reveal
atom
level
structur
analysi
accumul
evid
show
neutral
antibodi
therapeut
potenti
merscov
interfer
associ
rbd
addit
immunogen
rbd
undefin
ntermin
domain
ntd
account
larg
portion
may
serv
function
compon
merscov
subunit
ntd
recogn
receptorbind
site
sever
cov
includ
murin
hepat
viru
studi
discov
neutral
mab
specif
recogn
merscov
protein
ntd
studi
highlight
import
region
viral
infect
process
may
enabl
us
better
understand
underli
neutral
mechan
natur
merscov
infect
find
pave
way
merscov
vaccin
immunotherapi
develop
femal
balbc
mice
age
six
eight
week
use
mab
product
anim
studi
perform
strict
complianc
guid
care
use
laboratori
anim
peopl
republ
china
studi
protocol
approv
committe
ethic
anim
experi
chines
center
diseas
control
prevent
vero
cell
line
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
ps
lglutamin
hepe
nonessenti
amino
acid
ad
cell
cultur
cell
grown
rpmi
contain
fb
ps
lglutamin
hepe
fusion
immun
mous
spleen
cell
hybridoma
cultur
dmem
fb
hypoxanthin
aminopterin
thymidin
hat
ps
cell
cultur
co
reagent
purchas
gibco
life
technolog
grand
island
ny
usa
except
dmem
obtain
hyclon
life
technolog
south
logan
ut
usa
merscov
strain
kindli
provid
professor
ron
fouchier
erasmu
medic
centr
rotterdam
netherland
plasmid
e
plasmid
encod
envelopedefect
luciferaseexpress
genom
mice
immun
merscov
rs
combin
freund
complet
adjuv
sigma
st
loui
ca
usa
via
subcutan
immun
boost
twice
interv
begin
three
week
initi
immun
mice
kill
day
last
immun
splenocyt
fuse
mous
myeloma
cell
mab
gener
previous
describ
cell
collect
spleen
kill
anim
fuse
cultur
cell
ratio
presenc
sigma
hat
select
medium
use
fuse
hybridoma
cultur
incub
posit
hybridoma
select
use
rscoat
elisa
posit
clone
subject
limit
dilut
downstream
valid
largescal
mab
product
ascit
fluid
mice
inocul
hybridoma
collect
purifi
use
capryl
acidammonium
sulfat
precipit
assay
hitrap
protein
g
column
akta
system
ge
healthcar
isotyp
classif
purifi
mab
perform
use
pierc
rapid
elisa
mous
mab
isotyp
kit
pierc
rockford
il
usa
accord
manufactur
instruct
precis
determin
bind
region
mab
target
protein
merscov
truncat
fragment
rrbd
rntd
panel
peptid
supplementari
tabl
span
entir
merscov
ntd
use
coat
antigen
indirect
elisa
briefli
elisa
plate
corn
shanghai
china
asia
coat
recombin
protein
aa
peptid
overnight
block
mab
ad
well
incub
h
plate
incub
hrpconjug
secondari
antibodi
h
bind
activ
determin
nm
use
plate
reader
multiskan
antiinfluenza
viru
mab
use
assay
unrel
neg
control
prefus
mous
serum
use
posit
control
bind
kinet
affin
mab
purifi
rntd
analyz
surfac
plasmon
reson
spr
biacor
ge
healthcar
mab
immobil
protein
sensor
chip
via
bind
fc
region
pbspbuffer
ph
differ
concentr
purifi
rntd
nm
run
flow
rate
pbspbuffer
surfac
regener
mm
glycinehcl
ph
sensorgram
fit
bind
model
use
bia
evalu
softwar
ge
healthcar
purifi
merscov
rs
rntd
analyz
sdspolyacrylamid
gel
supplement
sd
boil
min
denatur
protein
transfer
nitrocellulos
membran
block
nonfat
milk
pbst
h
room
temperatur
probe
overnight
mab
prefus
mous
serum
dilut
membran
incub
dylight
igg
secondari
goat
antimous
igg
licor
bioscienc
ne
usa
scan
use
odyssey
infrar
imag
system
licor
bioscienc
lincoln
ne
usa
neutral
activ
select
mab
initi
determin
use
pseudovirus
describ
previous
identifi
novel
neutral
epitop
merscov
protein
panel
mab
target
protein
aa
gener
use
tradit
hybridoma
fusion
protocol
nine
rselisa
bind
mab
cover
rbd
ntd
outsid
two
region
select
clone
shown
figur
tabl
mab
bound
strongli
rs
aa
concentr
five
mab
bound
strongli
rrbd
aa
one
three
mab
bound
aa
rntd
aa
respect
next
assess
neutral
activ
nine
select
mab
tcid
merscov
pseudovirus
shown
figur
mab
exhibit
greater
neutral
potenc
compar
prefus
mous
serum
dilut
rrbdbind
mab
show
strongest
neutral
activ
anoth
two
mab
one
novel
rntdbind
mab
exhibit
effici
neutral
activ
five
mab
includ
mab
exhibit
less
neutral
activ
mab
therefor
select
character
evalu
determin
bind
effici
mab
sampl
dilut
fivefold
detect
use
merscov
rntdcoat
elisa
result
show
high
bind
affin
rntd
ec
approxim
figur
meanwhil
exhibit
crossreact
rrbd
even
concentr
figur
mab
evalu
parallel
unrel
neg
control
next
bind
rate
constant
mab
rntd
determin
spr
shown
figur
show
nanomolar
affin
rntd
equilibrium
dissoci
constant
kd
equival
nm
previou
result
show
exhibit
approxim
neutral
activ
toward
pseudoviru
merscov
concentr
determin
lowest
concentr
mab
effect
inhibit
pseudoviru
merscov
entri
use
twofold
dilut
mab
result
show
neutral
activ
dose
depend
ic
approxim
ic
antirbd
mab
lower
ic
figur
therefor
show
effici
neutral
activ
character
neutral
potenc
live
merscov
strain
also
determin
shown
figur
mab
neutral
live
merscov
infect
ic
imag
reduc
pfu
format
correspond
live
merscov
neutral
percentag
shown
figur
togeth
neutral
data
indic
merscov
ntd
may
play
import
role
viral
infect
process
character
bind
abil
mab
merscov
ntd
aa
employ
western
blot
assay
rntd
denatur
determin
epitop
conform
linear
result
show
mab
effici
bound
merscov
rntd
aa
rs
figur
aa
peptid
elisa
perform
locat
bind
site
result
show
bound
weakli
peptid
od
figur
supplementari
tabl
result
suggest
possibl
linear
bind
epitop
ntd
although
specif
region
clearli
determin
sever
studi
demonstr
potent
neutral
mab
merscov
deriv
human
murin
origin
target
rbd
region
protein
addit
mab
shown
promis
therapeut
valu
anim
model
rbdbase
vaccin
also
elicit
strong
humor
immun
respons
use
differ
immun
strategi
find
demonstr
mab
antibodi
specif
target
merscov
ntd
exhibit
effici
neutral
activ
merscov
although
vitro
neutral
potenc
ic
ml
approxim
lower
potenc
rbdtarget
mab
thu
mab
warrant
develop
evalu
anim
model
provid
altern
merscov
immunotherapi
viru
mutat
longer
remain
suscept
rbdspecif
mab
treatment
surfac
segment
major
cov
structur
protein
maintain
quaternari
natur
complex
vital
viral
infect
recent
one
studi
show
sarscov
infect
affect
inactivetoact
state
transit
glycoprotein
trimer
addit
loop
connect
ntd
ctermin
domain
ctd
found
play
key
role
conform
switch
lassa
viru
lasv
envelop
glycoprotein
complex
gpc
anoth
class
viral
fusion
protein
initi
infect
process
unusu
stabl
signal
peptid
ssp
respons
receptor
bind
mediat
fusion
virion
cell
membran
previou
studi
demonstr
gap
glycan
shield
lasv
gpc
permit
neutral
antibodi
interact
simultan
ntermin
extens
either
fusion
loop
tloop
inhibit
structur
alter
requir
fusion
discoveri
show
maintain
glycoprotein
structur
integr
viral
infect
necessari
neutral
mab
target
differ
surfac
glycoprotein
epitop
interfer
structur
state
switch
shown
figur
structur
dock
merscov
protein
reveal
ntd
ctermin
rbd
subunit
form
extens
quaternari
abbrevi
ntermin
domain
ntd
pseudoviru
merscov
neutral
mab
concentr
interact
featur
may
impli
certain
epitop
ntd
merscov
structur
function
close
one
rbd
mab
target
epitop
interfer
receptor
bind
postfus
stage
glycan
composit
class
envelop
glycoprotein
shield
viru
neutral
effect
mab
neutral
mab
envelop
glycoprotein
found
bind
residu
glycan
therebi
preclud
coreceptorinduc
conform
chang
requir
membran
fusion
protein
coronavirida
famili
consist
four
genera
also
class
envelop
glycoprotein
use
protein
rbd
ntd
interact
cellular
receptor
coreceptor
viral
attach
best
knowledg
includ
sarscov
merscov
use
protein
moieti
recognit
receptor
main
function
rbd
locat
ctd
contrast
rbd
bovin
cov
human
cov
one
avian
locat
ntd
sugar
moieti
main
receptor
notabl
ntd
ctd
two
porcin
epidem
diarrhea
cov
transmiss
gastroenter
might
play
vital
role
viral
infect
ntd
merscov
also
glycosyl
neutral
mab
may
bind
glycan
residu
ntd
stabil
prefus
conform
protein
interact
therebi
preclud
coreceptorinduc
conform
chang
requir
membran
fusion
continu
human
infect
merscov
global
public
health
concern
highlight
need
effici
countermeasur
current
variou
vaccin
therapeut
antibodi
merscov
develop
target
merscov
rbd
contain
variabl
region
multipl
evalu
full
length
sbase
truncat
vaccin
indic
increas
epitop
rang
would
import
futur
merscov
vaccin
design
studi
suggest
ntd
contain
neutral
epitop
consid
immunogen
compon
thu
propos
combin
promis
vaccin
candid
ntd
would
improv
protect
effect
also
reduc
likelihood
possibl
resist
develop
via
mutat
supplementari
tabl
peptid
coat
onto
plate
ngwell
mab
evalu
concentr
result
shown
repres
three
independ
experi
ntermin
domain
ntd
neutral
mab
target
merscov
ntd
chen
et
al
